Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Rebuffed, Hyseq Remains in Favor in Bid for Variagenics

NEW YORK, Jan. 21 - Hyseq's bid to buy Variagenics is still a go after the attention of another suitor was rebuffed, Variagenics said today.

 

CombiMatrix, owned by Acacia Research Corporation, made an unsolicited merger bid for Variagenics, the company said. The proposal included a stock-for-stock merger.

 

Variagenics board of directors voted down the proposal and reaffirmed their intention of merging with Hyseq, according to the company.

 

Click here for more information.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.